CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-30 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $52.14 | $261K | 397,456 |
| 2024-09-30 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 74,727 | ||
| 2024-09-17 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 128,220 |
| 2024-09-17 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $56.77 | $301K | 122,920 |
| 2024-09-17 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $56.76 | $114K | 120,920 |
| 2024-09-17 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 31,800 | ||
| 2024-09-16 | Blum Robert I President & CEO | Option exercise 10b5-1 | +5,000 | $6.67 | $33K | 402,456 |
| 2024-09-16 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $55.99 | $280K | 397,456 |
| 2024-09-16 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 79,727 | ||
| 2024-09-09 | PARSHALL B LYNNE Director | Option exercise 10b5-1 | +5,000 | $21.61 | $108K | 25,600 |
| 2024-09-09 | PARSHALL B LYNNE Director | Sale 10b5-1 | −5,000 | $54.92 | $275K | 20,600 |
| 2024-09-09 | PARSHALL B LYNNE Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 0 | ||
| 2024-09-03 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 128,220 |
| 2024-09-03 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,084 | $56.99 | $119K | 122,920 |
| 2024-09-03 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $57.02 | $302K | 122,920 |
| 2024-09-03 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 37,100 | ||
| 2024-09-03 | Blum Robert I President & CEO | Option exercise 10b5-1 | +5,000 | $6.67 | $33K | 402,456 |
| 2024-09-03 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $57.03 | $285K | 397,456 |
| 2024-09-03 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 84,727 | ||
| 2024-08-30 | Pletcher Brett A EVP, Chief Legal Officer | Grant or award | +33,140 | 33,140 |
Page 28 of 33 · 660 trades